Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;38(10):2266-2269.
doi: 10.1038/s41375-024-02378-5. Epub 2024 Aug 21.

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Eduardo Rodríguez-Arbolí  1   2 , Megan Othus  3 , Sylvie D Freeman  4 , Francesco Buccisano  5 , Lok Lam Ngai  6 , Ian Thomas  7 , Raffaele Palmieri  5 , Jacqueline Cloos  6 , Sean Johnson  7 , Elisa Meddi  5 , Nigel H Russell  8 , Adriano Venditti  5 , Patrycja Gradowska  9 , Gert J Ossenkoppele  6 , Bob Löwenberg  10 , Roland B Walter  11   12   13
Affiliations

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Eduardo Rodríguez-Arbolí et al. Leukemia. 2024 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

E.R.A. has been a consultant to Astellas and Laboratoires Delbert, and received travel grants and/or speaker fees from AbbVie, Astellas, Eurocept, Gilead, and Jazz Pharmaceuticals. M.O. has been a consultant to Biosight and Merck and served on Data Safety Monitoring Boards for Celgene/Bristol Myers Squibb, Grifols, and Glycomimetics. S.D.F. has been a consultant to MPAACT; institute research funding from Bristol Myers Squibb, and Jazz Pharmaceuticals. F.B. has been a consultant to Jazz Pharmaceuticals, Laboratoires Delbert, and Novartis, received research funding from Becton Dickinson, and received speaker fees from AbbVie, Astellas, Bristol Myers Squibb, Janssen-Cilag, and Jazz Pharmaceuticals. J.C. received speaker fees from Astellas; institute receives royalties from BD Biosciences and Navigate, and institute receives research funding from Genentech, Novartis, and Takeda. R.B.W. received laboratory research grants and/or clinical trial support from Aptevo, Celgene/Bristol Myers Squibb, ImmunoGen/AbbVie, Janssen, Jazz, Kite, Kura, Pfizer, and VOR, and has been a consultant to Wugen. All other authors declare no competing conflict of interest.

Figures

Figure 1.
Figure 1.
Cumulative incidence of relapse after chemotherapy cycle 2 in the (A) GIMEMA, (B) HOVON/SAKK, and (C) MRC/NCRI cohorts, and pre-HCT in the (D) Seattle cohort, stratified by MFC-MRD level.
See this image and copyright information in PMC

References

    1. Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12): 1275–1291. - PMC - PubMed
    1. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138(26): 2753–2767. - PMC - PubMed
    1. Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hemasphere 2022; 6(1): e676. - PMC - PubMed
    1. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96(12): 3948–3952. - PubMed
    1. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 2006; 20(10): 1783–1789. - PubMed

LinkOut - more resources